Parkinsonism & Related Disorders
Volume 15, Issue 9 , Pages 660-664 , 5 November 2009

Diabetes preceding Parkinson's disease onset. A case–control study

Received 1 July 2008 ,Revised 23 February 2009 ,Accepted 27 February 2009.

References 

  1. Struck LK, Rodnitzky RL, Dobson JK. Stroke and its modification in Parkinson's disease. Stroke. 1990;21:1395–1399
  2. Rajput AH, Offord KP, Beard CM, Kurland LT. A case–control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology. 1987;37:226–232
  3. Levine RL, Jones JC, Bee N. Stroke and Parkinson's disease. Stroke. 1992;23:839–842
  4. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994;44:1865–1868
  5. Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S, et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003;60:87–93
  6. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord. 2004;19:49–53
  7. Nataraj A, Rajput AH. Parkinson's disease, stroke, and related epidemiology. Mov Disord. 2005;20:1476–1480
  8. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord. 2006;12:185–189
  9. Leibson CL, Maraganore DM, Bower JH, Ransom JE, O'brien PC, Rocca WA. Comorbid conditions associated with Parkinson's disease: a population-based study. Mov Disord. 2006;21:446–455
  10. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case–control study. Stroke. 2006;37:1184–1188
  11. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care. 2007;30:842–847
  12. Arvanitakis Z, Wilson RS, Bienias JL, Bennett DA. Diabetes and parkinsonian signs in older persons. Alzheimer Dis Assoc Disord. 2007;21:144–149
  13. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69:1688–1695
  14. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signaling mechanisms and functional aspects. Prog Neurobiol. 1991;36:343–352
  15. Will JC, Galuska DA, Ford ES, Mokdad A, Calle EE. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int J Epidemiol. 2001;30:540–546
  16. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004;27:561–568
  17. Di Monte D, Sandy MS, Blank L, Smith MT. Fructose prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced ATP depletion and toxicity in isolated hepatocytes. Biochem Biophys Res Commun. 1988;153:734–740
  18. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology. 1999;69:160–166
  19. Sirtori CR, Bolme P, Azarnoff DL. Metabolic responses to acute and chronic l-DOPA administration in patients with parkinsonism. N Engl J Med. 1972;287:729–733
  20. Ragonese P, D'Amelio M, Salemi G, Aridon P, Gammino M, Epifanio A, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology. 2004;62:2010–2014
  21. Morgante L, Rocca WA, Di Rosa AE, De Domenico P, Grigoletto F, Meneghini F, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1992;42:1901–1907
  22. Brocco S, Visentin C, Fedeli U, Schievano E, Avogaro A, Andretta M, et al. Monitoring the occurrence of diabetes mellitus and its major complications: the combined use of different administrative databases. Cardiovasc Diabetol. 2007;15(6):5
  23. Barbeau A. Experience clinique avec le tolbutamide dans la maladie de Parkinson. Union Med Can. 1961;90:147–151
  24. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci. 1993;69:125–130
  25. Sandyk R, Awerbuch GI. The association of diabetes mellitus with dementia in Parkinson's disease. Int J Neurosci. 1992;64:209–212
  26. Kriegsman DM, Penninx BW, van Eijk JT, Boeke AJ, Deeg DJ. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy. J Clin Epidemiol. 1996;49:1407–1417
  27. Milne JC, Denu JM. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol. 2008;12:11–17
  28. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342
  29. Dillin A, Kelly JW. The yin-yang of sirtuins. Science. 2007;317:461–462
  30. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007;317:516–519

PII: S1353-8020(09)00062-5

doi: 10.1016/j.parkreldis.2009.02.013

Parkinsonism & Related Disorders
Volume 15, Issue 9 , Pages 660-664 , 5 November 2009

Article Tools